Warren-based Tevogen on Thursday said it signed a letter of intent to lease a 17,428-square-foot facility that should support the company’s cell therapy manufacturing operations. The space, formerly occupied by Pfizer and Cordis, a previous division of Johnson & Johnson, aligns with Tevogen’s goals of accelerating clinical development while maintaining cost efficiency and scalability.
“Our continued investment in infrastructure reflects our commitment to delivering innovative and accessible T cell therapies,” Dr. Ryan Saadi, CEO of Tevogen Bio said. “This facility has potential to efficiently scale our manufacturing as we advance our pipeline toward commercialization and will serve as a bridge as we enter the early stages of developing our own custom-built manufacturing facility.”
The facility’s intended use will be for GMP cell therapy manufacturing and complement Tevogen’s anticipated growing pipeline powered by PredicTcell™, the company’s proprietary AI-driven target discovery platform. The lease term is expected to be greater than five years and the company expects to begin occupancy following final lease execution and completion of necessary approvals.
This announcement comes on the heals of the firm’s completed an expansion project on its corporate headquarters site in Warren, the build-out, fully funded by Saadi, more than doubles Tevogen’s previous footprint and brings research, regulatory, and the expanding Tevogen.AI teams together under one roof.
